Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$96.80 USD

96.80
523,757

-0.91 (-0.93%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $96.80 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (58 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Zacks News

Buy These 5 Low Leverage Stocks on Chances of Rate Hike

Prudent investors try to avoid companies with large debt loads since they are more vulnerable during economic downturns.

    Brush Off Volatility Concerns With These 5 Low-Beta Stocks

    We create a strategy that singles out less-risky stocks which can generate impressive returns only when certain parameters are considered.

      Ritujay Ghosh headshot

      5 Knockout Stocks to Play the World Cup Fever Pitch

      Much like any tournament can't be won without putting up a strong fight, markets too go through ups and downs. Amid all the odds, stock winners leave a mark with their performance.

        Is Amedisys (AMED) a Great Growth Stock?

        Amedisys (AMED) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.

          QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth

          QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.

            Buy These 5 Low Leverage Stocks Amid Rising Trade Tensions

            For a safe investment strategy, understanding the amount of financial leverage that a company bears is crucial. This is because financial leverage multiplies the underlying business risk.

              Hologic's New Panther Fusion System Gets Health Canada Nod

              Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.

                Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.

                  Medtronic's Expanded IN.PACT Admiral FDA Nod to Aid APV Arm

                  Medtronic's (MDT) receipt of FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.

                    Envision Healthcare's (EVHC) Ratings on Review for Downgrade

                    Moody's Investor Service puts Envision Healthcare's (EVHC) ratings and outlook on review for downgrade.

                      Zacks.com highlights: G-III Apparel Group, Momo, Weight Watchers International, Amedisys and Urban Outfitters

                      Zacks.com highlights: G-III Apparel Group, Momo, Weight Watchers International, Amedisys and Urban Outfitters

                        CVS Health's PBM Selling Season Remains Solid, Retail Grows

                        CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.

                          Nilanjan Choudhury headshot

                          5 Stocks to Snap Up on Explosive Relative Price Strength

                          Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.

                            Top Ranked Momentum Stocks to Buy for June 11th

                            Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 11th:

                              Top Ranked Momentum Stocks to Buy for June 8th

                              Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 8th:

                                Here's Why You Should Invest in Genomic Health (GHDX) Now

                                Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.

                                  ResMed Reports Positive Results for Bilevel PAP Device Study

                                  Positive results from the Bilevel Rescue study are expected to boost the uptake of ResMed's (RMD) bilevel devices.

                                    Why Amedisys (AMED) Stock Might be a Great Pick

                                    Amedisys (AMED) is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.

                                      Amedisys (AMED) Up 17% Since Earnings Report: Can It Continue?

                                      Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        Amedisys (AMED) Buys Back 2.4M Shares From KKR, Stock Up

                                        Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.

                                          Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe

                                          The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.

                                            Buy These 5 Low Leverage Stocks to Secure Your Portfolio

                                            The stage is set for the U.S. market to be on an upward trajectory, raising hopes for upswings in the future. Yet investors should calculate a company's leverage before investing in the stock.

                                              Boston Scientific Grows on New Products Amid Recall Issues

                                              Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.

                                                Bruker Unveils New Mass-Spectrometry Products, Boosts CALID

                                                Bruker's (BRKR) mass-spectrometry business within its CALID group rides high on strong sales performances in recent times.

                                                  Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.

                                                  Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.